In 2020, some 70 percent of new clinical trials were sponsored by smaller pharma companies, up from 60 percent in 2016. Unprecedented levels of venture-capital investment and increasing availability and breadth of outsourced capacity and capabilities paved the way for smaller companies to pursue innovation.
![Make way for new players](/~/media/mckinsey/featured%20insights/charting%20the%20path%20to%20the%20next%20normal/2022/may/gifs%20and%20modified%20charts/pub-pharmapipeline-v9-rj-shrunk-timed.gif)
To read the article, see “Building pharma pipelines using a socioeconomic lens,” April 8, 2022.